Why it matters: The decision removes one of Ipsen’s two experimental MAPK-pathway inhibitors for solid tumours and returns a clinical-stage programme to the small French biotech that discovered it.

Why it matters: BioNTech’s decision provides a powerful external endorsement of Oelkers’ record at Sobi. Oelkers did not create Sobi’s scientific foundations, but he built a much larger commercial and dealmaking organization around them, expanding the company in the U.S. and adding a succession of acquired and licensed rare disease products. BioNTech is now hiring him for a similar company-building challenge: scaling an innovation-driven biotech as it prepares to launch multiple products.

Plants already have the tools to respond to a range of biotic and abiotic threats. The problem, says North Carolina-base…

The signals that cells use to switch genes on have remained almost unchanged across two billion years of evolution, but the ones used to switch genes off vary dramatically from one branch of life to another, according to a new study by researchers at the Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST).

世界农化网中文网报道：近日，利尔化学股份有限公司接受申万宏源、永赢基金等特定对象调研，公司董事长尹英遂、副总经理/董事会秘书刘军、董事会办公室主任/证券事务代表靳永恒，以及及董事会办公室刘妤出席本次投资者关系活动，主要交流问题如下：

“Innovation has to start with listening,” says Dr. William Aderholdt, executive director of US-based agtech …

Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and guide focused optimization cycles.

Why it matters: The transaction would rank among the largest pharmaceutical deals ever and create the world’s fourth-largest drugmaker by market value. It would also represent a sharp strategic turn for AstraZeneca, which has spent the past decade building its pipeline through targeted acquisitions and licensing deals rather than another industry-defining merger.

世界农化网中文网报道：当地时间2026年7月30日，中农立华国际业务旗下SINO-AGRI Argentina品牌暨新品发布会在阿根廷罗萨里奥举办。本次盛会是继2023年杭州全球品牌焕新首发后，在南美市场持续推进品牌建设与本地化运营的重要一步。通过此次发布会，公司进一步展示了在产品开发、登记布局、供应链管理和市场服务等方面的综合能力，并明确了以阿根廷为重要支点，持续深化南美市场发展的长期方向。